{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:40:10Z","timestamp":1759462810033,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1053\/j.ajkd.2017.06.009","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T08:17:25Z","timestamp":1505895445000},"page":"456-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autosomal Dominant PKD in Patients With PKD2 Mutations\u2013A\u00a0Benign Disorder?"],"prefix":"10.1053","volume":"70","author":[{"given":"Ahsan","family":"Alam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2017.06.009_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2017.06.009_bib2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","article-title":"PKD2-related autosomal dominant polycystic kidney disease: prevalence, clinical presentation, mutation spectrum, and prognosis","volume":"70","author":"Cornec-Le Gall","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"9147","key":"10.1053\/j.ajkd.2017.06.009_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2017.06.009_bib4","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2017.06.009_bib5","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1681\/ASN.2009020162","article-title":"Family history of renal disease severity predicts the mutated gene in ADPKD","volume":"20","author":"Barua","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2017.06.009_bib6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2017.06.009_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1053\/j.ajkd.2015.01.030","article-title":"Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy","volume":"66","author":"Alam","year":"2015","journal-title":"Am J Kidney Dis"},{"unstructured":"Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM458483.pdf. Accessed July 21, 2017.","key":"10.1053\/j.ajkd.2017.06.009_bib8"},{"unstructured":"Qualification opinion: Total Kidney Volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients\u00a0with Autosomal Dominant Polycystic Kidney Disease (ADPKD). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2015\/11\/WC500196569.pdf. Accessed July 21, 2017.","key":"10.1053\/j.ajkd.2017.06.009_bib9"},{"issue":"3","key":"10.1053\/j.ajkd.2017.06.009_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","article-title":"Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2017.06.009_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ekir.2017.02.011","article-title":"A\u00a0drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"unstructured":"Classification of Typical ADPKD Calculator. http:\/\/www.mayo.edu\/research\/documents\/pkd-center-adpkd-classification\/doc-20094754. Accessed July 21, 2017.","key":"10.1053\/j.ajkd.2017.06.009_bib12"},{"issue":"1","key":"10.1053\/j.ajkd.2017.06.009_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617307898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617307898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:58:34Z","timestamp":1759460314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617307898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0272638617307898"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.06.009","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autosomal Dominant PKD in Patients With PKD2 Mutations\u2013A\u00a0Benign Disorder?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.01.046","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}